| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,150,000 |
| Market
Cap: |
537.01(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1294 - $1.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using Co.'s ADAPTIR™ modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform. The ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mitchell Shawnte |
SVP, GC and Corporate Affairs |
• – – |
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,787 |
82,539 |
|
- |
|
| Maddux Randy Joe |
SVP Operations |
• – – |
2018-12-06 |
4 |
B |
$2.37 |
$11,850 |
D/D |
5,000 |
30,000 |
2.74 |
- |
|
| White Marvin L |
President and CEO |
• • – |
2018-12-04 |
4 |
B |
$2.38 |
$23,800 |
D/D |
10,000 |
203,603 |
2.81 |
- |
|
| Mitchell Shawnte |
SVP, GC and Corporate Affairs |
• – – |
2018-08-09 |
4 |
D |
$4.50 |
$1,724 |
D/D |
(383) |
75,752 |
|
- |
|
| Mitchell Shawnte |
SVP, GC and Corporate Affairs |
• – – |
2018-08-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,630 |
76,135 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2018-05-21 |
4 |
D |
$5.61 |
$46,973 |
D/D |
(8,373) |
193,603 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2018-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,644 |
201,976 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2018-03-19 |
4/A |
B |
$2.93 |
$293,000 |
D/D |
100,000 |
166,332 |
2.81 |
- |
|
| White Marvin L |
President and CEO |
• • – |
2018-03-19 |
4 |
S |
$2.93 |
$293,000 |
D/D |
(100,000) |
166,332 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-03-10 |
4 |
D |
$3.13 |
$4,955 |
D/D |
(1,583) |
69,876 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,747 |
71,459 |
|
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2018-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,892 |
204,737 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2018-03-09 |
4 |
D |
$3.13 |
$7,143 |
D/D |
(2,282) |
103,155 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2018-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,728 |
105,437 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2018-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,140 |
95,709 |
|
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2018-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,269 |
190,845 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-03-01 |
4 |
D |
$3.04 |
$5,220 |
D/D |
(1,717) |
64,712 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,320 |
66,429 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-02-03 |
4 |
D |
$3.24 |
$24,345 |
D/D |
(7,514) |
59,109 |
|
- |
|
| Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
• – – |
2018-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,340 |
66,623 |
|
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2018-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,381 |
174,576 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2018-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,136 |
86,569 |
|
- |
|
| Maddux Randy Joe |
Senior VP, Operations |
• – – |
2017-11-15 |
4 |
B |
$2.76 |
$69,000 |
D/D |
25,000 |
25,000 |
2.74 |
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2017-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
78,123 |
147,195 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2017-08-01 |
4 |
D |
$1.83 |
$18,439 |
D/D |
(10,076) |
68,433 |
|
- |
|
128 Records found
|
|
Page 4 of 6 |
|
|
